NSG immunodeficient mouse only (xenograft of transduced human CD34+ cells)
“The use of NSG mouse strain (deficient in mature T/B/NK cells) for the non-clinical biodistribution/single-dose toxicology study after engraftment of CD34+ cells derived from healthy human UCB, transduced with GSK3336223 vector, was endorsed by the CAT/CHMP prior to MAA submission.”
NSG supports human HSPC engraftment with longer survival and fewer spontaneous tumours than ADA-/- mice; no cross-reactivity issue (human cells)
“Subsequently, the results of two bio-distribution studies were submitted using the NSG mouse based on the reports presented that indicate this is a valid model for immunodeficient mice, which can be used as recipient of HSPC transplantation, with longer survival rates and reduced frequency of spontaneous tumours as compared to ADA-/- mice.”
Yes: healthy-donor cord blood CD34+ cells transduced with clinical RV (GSK3235757A); murine lin- BM cells for oncogenicity pilots
“The test item used in the biodistribution studies (referred to as GSK3235757A) comprised of CD34+ cells derived from healthy human UCB transduced with GSK3336223 vector and is accepted as representative of Strimvelis.”